NPM1 and Friedreich ataxia: In conclusion, we report a unique scenario of NPM1-mutated DCL in a patient with FA where MRD-negative remission with limited toxicity was achieved using venetoclax/azacitidine before HSCT, and the patient remains disease-free for over a year after HSCT.